UK fi­bro­sis biotech Redx Phar­ma is mak­ing an­oth­er go at a re­verse merg­er, af­ter its last at­tempt was axed in 2023.

The ROCK in­hibitor...

Af­ter a neg­a­tive FDA ad­vi­so­ry com­mit­tee vote, Capri­cor Ther­a­peu­tics said it will file ad­di­tion­al da­ta and analy­ses on its Duchenne mus­cu­lar dy­s­tro­phy ther­a­py in hopes...

Abcuro has col­lect­ed $66 mil­lion a few months af­ter say­ing its sole drug missed the mark in a mus­cle-weak­en­ing con­di­tion but had found hope in...

⏸️ Map­Light Ther­a­peu­tics paus­es pre­clin­i­cal and dis­cov­ery work: The biotech saidit will in­stead fo­cus its re­sources on ad­vanc­ing its lead can­di­date, ML-007C-MA, for schiz­o­phre­nia...